Sir Graham Brady MP appointed to the board of Medannex

  • Medannex strengthens its board ahead of clinical expansion


Medannex Ltd (Edinburgh) announced today that Sir Graham Brady has been appointed as a non-executive director of the company as of 1 February 2024.

Currently a Member of Parliament at Westminster, Sir Graham has had a remarkable political career, having held a range of senior positions. The post for which he is perhaps best known is as the longstanding Chair of the 1922 Committee. He will stand down as an MP at the next general election and plans to devote his time to helping the growth of British business. Sir Graham brings a wealth of experience to Medannex as the company embarks on an ambitious programme of clinical trials.

Sir Graham said: “I am delighted to be joining the team of this young and exciting life sciences company. Medannex has won awards for its pioneering work in areas of unmet medical need and I look forward to being an active part of its continued progress. The UK is looking to companies like Medannex for the next phase of our country’s growth.”

Professor Christopher Wood, Medannex’s Chairman, added: “It’s a real pleasure to welcome Sir Graham to the board of directors of Medannex. He adds a new and important dimension to the company in its quest to develop new treatments for cancer and autoimmune diseases.”

Medannex has a new, first-in-class medicine (MDX-124) currently undergoing clinical trials at three major cancer centres in the UK. MDX-124 has the potential to offer significant clinical benefit in the treatment of many cancers - including pancreas, triple-negative breast, colorectal and lung - as well as autoimmune diseases such as multiple sclerosis, systemic lupus and rheumatoid arthritis. MDX-124 also has potential as a treatment for certain childhood cancers, an opportunity that the company is exploring in the UK and the USA.

Medannex CEO Ian Abercrombie said: ‘”In Medannex we are developing a new treatment with huge potential, and with a magnificent and dedicated team to make it happen. The addition of a board member with the stature of Sir Graham Brady is a tremendous encouragement to the team and our shareholders.”



More news and updates 

RSSL announces new Biotech Innovation Hub

RSSL, a leading pharmaceutical contract research organisation, has today announced plans to launch its new Innovation Hub, a dedicated platform to help small- and medium-sized biotech organisations de-risk and accelerate the development of cutting-edge products.

Aleta Biotherapeutics and Cancer Research UK announce first patient dosed in ALETA-001 Phase 1/2 clinical trial

The Phase 1/2 clinical trial will evaluate safety, dose, PK/PD, and early efficacy signals of Aleta’s first-in-class biologic CAR T-cell engager, ALETA-001. ALETA-001 entering the clinic is a critical milestone toward treatment availability to improve CAR T-cell patient response when a complete response is not achieved or maintained.

UKHSA announced as first PACE collaboration to help tackle deadly antimicrobial resistance

Strategic partnership to support AMR innovators

PrecisionLife and Metrodora Institute partner to accelerate diagnosis of Long COVID

Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases; targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year

Optibrium enables collaborative design in its StarDrop platform

The new Idea Tracker capability further improves the efficiency of drug discovery by supporting project management, idea sharing and molecule design tracking.

BugBiome secures investment for pioneering research in sustainable pest protection

BugBiome raises £310,000 in pre-seed investment from Cambridge Angels and Discovery Park Ventures. Investment enables a £330,000 Engineering Biology Grant from Innovate UK for cutting-edge agri-tech research leveraging the microbiome and engineering biology approaches.

Study reveals POLB 001 could be a $10 billion game changer for cancer patients

Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS). Former Amryt Pharma team's arrival supports increasing focus upon Rare and Orphan Diseases

Demand for Golden Triangle lab space surges with highest annual volume since 2015

Demand for life sciences space in the ‘Golden Triangle’ surged in 2023, with the 925,000 sq ft of space representing the highest annual volume since 2015, according to the latest figures from Cushman & Wakefield.

New £100 million engineering biology fund

Six new Engineering Biology Mission Hubs and 22 Mission Awards, to transform solutions in areas like vaccine development, textile manufacturing and food production; New investments to unlock potential of engineering biology as part of the wider National Engineering Biology Programme

Pioneer Group’s regeneration plans for Cambridge’s Grafton Centre approved

Pioneer Group, a leading developer and operator of life science and high-tech campuses, has secured planning permission from Cambridge City Council, subject to S106, for the redevelopment of the Grafton Centre in the city.

 

More within